HomepageNVAX • NASDAQ
add
Novavax Inc
$ 6,80
Na sluitingstijd:(0,44%)+0,030
$ 6,83
Gesloten: 3 jul, 17:00:00 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 6,76
Dag-range
$ 6,72 - $ 6,87
Jaar-range
$ 5,01 - $ 17,81
Beurswaarde
1,10 mld. USD
Gem. volume
6,64 mln.
Koers/winst
2,55
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 666,66 mln. | 610,30% |
Bedrijfskosten | 47,59 mln. | -42,17% |
Netto inkomsten | 518,65 mln. | 451,51% |
Netto winstmarge | 77,80 | 149,49% |
Winst per aandeel | 2,93 | 379,05% |
EBITDA | 524,35 mln. | 514,23% |
Effectief belastingtarief | 0,23% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 731,48 mln. | 52,21% |
Totale activa | 1,29 mld. | -4,47% |
Totale passiva | 1,37 mld. | -38,37% |
Totaal aandelenvermogen | -75,64 mln. | — |
Uitstaande aandelen | 161,97 mln. | — |
Koers-boekwaardeverhouding | -14,38 | — |
Rendement op activa | 90,42% | — |
Rendement op kapitaal | -1.244,28% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 518,65 mln. | 451,51% |
Operationele kasstroom | -185,50 mln. | -122,01% |
Kasstroom uit beleggingen | -73,32 mln. | -911,30% |
Kasstroom uit financiering | -7,06 mln. | -219,96% |
Nettomutatie in liquide middelen | -266,81 mln. | -203,63% |
Vrije kasstroom | -315,38 mln. | 42,96% |
Over
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Opgericht
1987
Hoofdvestiging
Website
Werknemers
952
